QURE Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the uniQure N.V. Class Action

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired shares of uniQure N.V. between September 24, 2025, and October 31, 2025, due to allegations of misleading information regarding the FDA approval process for its drug candidate AMT-130 [1][2]. Group 1: Allegations and Impact - The lawsuit alleges that uniQure misled investors by failing to disclose that the design of its pivotal study was not fully approved by the FDA and that the company downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline for additional studies [2]. - On November 3, 2025, uniQure announced that the FDA no longer agreed that the data from its Phase I/II studies would be adequate for BLA submission, leading to a significant drop in share price from $67.69 to $34.29, a decline of over 49% [3]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit their papers by April 13, 2026, and participation in the case is not required to be eligible for recovery [4]. - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses for representation [5].